264 related articles for article (PubMed ID: 30104997)
1. Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Wang L; Li J; Chen J
Front Neurol; 2018; 9():620. PubMed ID: 30104997
[No Abstract] [Full Text] [Related]
2. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Wirdefeldt K; Odin P; Nyholm D
CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
[TBL] [Abstract][Full Text] [Related]
3. Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis.
Liu XD; Bao Y; Liu GJ
Front Neurol; 2019; 10():934. PubMed ID: 31507529
[No Abstract] [Full Text] [Related]
4. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
[TBL] [Abstract][Full Text] [Related]
6. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
[TBL] [Abstract][Full Text] [Related]
7. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
[TBL] [Abstract][Full Text] [Related]
9. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
[TBL] [Abstract][Full Text] [Related]
10. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
[TBL] [Abstract][Full Text] [Related]
11. Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa.
Kulisevsky J; Bejr-Kasem H; Martinez-Horta S; Horta-Barba A; Pascual-Sedano B; Campolongo A; Marín-Lahoz J; Aracil-Bolaños I; Pérez-Pérez J; Izquierdo-Barrionuevo C; de Fàbregues O; Puente V; Crespo-Cuevas A; Calopa M; Pagonabarraga J
J Neurol; 2020 Nov; 267(11):3400-3410. PubMed ID: 32607644
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age.
Morgante F; Oppo V; Fabbri M; Olivola E; Sorbera C; De Micco R; Ielo GC; Colucci F; Bonvegna S; Novelli A; Modugno N; Sensi M; Zibetti M; Lopiano L; Tessitore A; Pilleri M; Cilia R; Elia AE; Eleopra R; Ricciardi L; Cossu G
J Neurol; 2021 May; 268(5):1728-1737. PubMed ID: 33354739
[TBL] [Abstract][Full Text] [Related]
13. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
[TBL] [Abstract][Full Text] [Related]
14. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
Buongiorno M; Antonelli F; Cámara A; Puente V; de Fabregues-Nebot O; Hernandez-Vara J; Calopa M; Pascual-Sedano B; Campolongo A; Valldeoriola F; Tolosa E; Kulisevsky J; Martí MJ
Parkinsonism Relat Disord; 2015 Aug; 21(8):871-6. PubMed ID: 26003410
[TBL] [Abstract][Full Text] [Related]
15. 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease.
Cruse B; Morales-Briceño H; Chang FCF; Mahant N; Ha AD; Kim SD; Wolfe N; Kwan V; Tsui DS; Griffith JM; Galea D; Fung VSC
NPJ Parkinsons Dis; 2018; 4():34. PubMed ID: 30480087
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
17. Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia.
Fabbri M; Zibetti M; Calandra-Buonaura G; Contin M; Sambati L; Mohamed S; Romagnolo A; Berchialla P; Imbalzano G; Giannini G; Rizzone MG; Artusi CA; Cortelli P; Lopiano L
Mov Disord Clin Pract; 2020 Nov; 7(8):930-939. PubMed ID: 33163564
[TBL] [Abstract][Full Text] [Related]
18. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
Meloni M; Solla P; Mascia MM; Marrosu F; Cannas A
Parkinsonism Relat Disord; 2017 Apr; 37():92-96. PubMed ID: 28063683
[TBL] [Abstract][Full Text] [Related]
19. Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
Guthikonda LN; Lyons KE; Pahwa R
J Comp Eff Res; 2014 Jul; 3(4):331-3. PubMed ID: 25275230
[TBL] [Abstract][Full Text] [Related]
20. What can we learn from the effect of trihexyphenidyl on motor fluctuations during continuous levodopa-carbidopa intestinal gel infusion (LCIG)? - First documented case.
Kubo SI; Nakamura K; Tada Y; Kashio N; Yamashita S
Clin Park Relat Disord; 2020; 3():100071. PubMed ID: 34316650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
